Abstract
Background: In infants, distinct nasopharyngeal bacterial microbiotas differentially associate with the incidence and severity of acute respiratory tract infection and childhood asthma development. Objective: We hypothesized that distinct nasal airway microbiota structures also exist in children with asthma and relate to clinical outcomes. Methods: Nasal secretion samples (n = 3122) collected after randomization during the fall season from children with asthma (6-17 years, n = 413) enrolled in a trial of omalizumab (anti-IgE) underwent 16S rRNA profiling. Statistical analyses with exacerbation as the primary outcome and rhinovirus infection and respiratory illnesses as secondary outcomes were performed. Using A549 epithelial cells, we assessed nasal isolates of Moraxella, Staphylococcus, and Corynebacterium species for their capacity to induce epithelial damage and inflammatory responses. Results: Six nasal airway microbiota assemblages, each dominated by Moraxella, Staphylococcus, Corynebacterium, Streptococcus, Alloiococcus, or Haemophilus species, were observed. Moraxella and Staphylococcus species–dominated microbiotas were most frequently detected and exhibited temporal stability. Nasal microbiotas dominated by Moraxella species were associated with increased exacerbation risk and eosinophil activation. Staphylococcus or Corynebacterium species–dominated microbiotas were associated with reduced respiratory illness and exacerbation events, whereas Streptococcus species–dominated assemblages increased the risk of rhinovirus infection. Nasal microbiota composition remained relatively stable despite viral infection or exacerbation; only a few taxa belonging to the dominant genera exhibited relative abundance fluctuations during these events. In vitro, Moraxella catarrhalis induced significantly greater epithelial damage and inflammatory cytokine expression (IL-33 and IL-8) compared with other dominant nasal bacterial isolates tested. Conclusion: Distinct nasal airway microbiotas of children with asthma relate to the likelihood of exacerbation, rhinovirus infection, and respiratory illnesses during the fall season.
| Original language | English |
|---|---|
| Pages (from-to) | 1187-1197 |
| Number of pages | 11 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 144 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2019 |
Keywords
- 16S rRNA
- Microbiota
- Moraxella species
- Staphylococcus species
- airway
- asthma
- exacerbation
- rhinovirus
Fingerprint
Dive into the research topics of 'Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma. / National Institute of Allergy and Infectious Diseases–sponsored Inner-City Asthma Consortium.
In: Journal of Allergy and Clinical Immunology, Vol. 144, No. 5, 11.2019, p. 1187-1197.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma
AU - National Institute of Allergy and Infectious Diseases–sponsored Inner-City Asthma Consortium
AU - McCauley, Kathryn
AU - Durack, Juliana
AU - Valladares, Ricardo
AU - Fadrosh, Douglas W.
AU - Lin, Din L.
AU - Calatroni, Agustin
AU - LeBeau, Petra K.
AU - Tran, Hoang T.
AU - Fujimura, Kei E.
AU - LaMere, Brandon
AU - Merana, Geil
AU - Lynch, Kole
AU - Cohen, Robyn T.
AU - Pongracic, Jacqueline
AU - Khurana Hershey, Gurjit K.
AU - Kercsmar, Carolyn M.
AU - Gill, Michelle
AU - Liu, Andrew H.
AU - Kim, Haejin
AU - Kattan, Meyer
AU - Teach, Stephen J.
AU - Togias, Alkis
AU - Boushey, Homer A.
AU - Gern, James E.
AU - Jackson, Daniel J.
AU - Lynch, Susan V.
N1 - Funding Information: Disclosure of potential conflict of interest: All authors, with the exception of A. Togias, report grants from the National Institutes of Health (NIH) during the conduct of study. R. Valladares reports personal fees for employment with Siolta Therapeutics outside the submitted work. H. T. Tran reports personal fees from GlaxoSmithKline outside the submitted work. J. Pongracic reports provision of study drug for other asthma and allergy studies from GlaxoSmithKline, Boehringer Ingelheim, and Genentech/Novartis outside the submitted work. C. M. Kercsmar reports personal fees from GlaxoSmithKline for service on a DSMB and royalties from UpToDate outside the submitted work. M. Gill reports honoraria and support for travel from the American Academy of Allergy, Asthma & Immunology (AAAAI), as well as payment for lectures from the American Academy of Pediatrics outside the submitted work. A. H. Liu reports personal fees from Merck Sharp & Dohme and Phadia Thermo-Fisher and membership on a Data Monitoring Committee for GlaxoSmithKline outside the submitted work. M. Kattan reports personal feed from Novartis Pharma and Regeneron for service on advisory boards outside the submitted work. S. J. Teach reports grants from Patient-Centered Outcomes Research Institute ( PCORI) , EJF, and the NIH / National Heart, Lung, and Blood Institute (NHLBI) outside the submitted work and personal fees from UpToDate outside the submitted work. H. A. Boushey serves as a compensated member of a Scientific Advisory Committee for Siolta Therapeutics. J. E. Gern reports personal fees from PREP Biopharm, Regeneron, Meissa Vaccines, MedImmune, and Ena Pharmaceuticals, as well as stock options from Meissa Vaccines outside the submitted work and has a patent “Methods of Propagating Rhinovirus C in Previously Unsusceptible Cell Lines” issued and a patent “Adapted Rhinovirus C” pending outside the submitted work. D. J. Jackson reports personal fees from Novartis, Boehringer Ingelheim, Pfizer, Commense, and Sanofi/Genzyme outside the submitted work, as well as grants from GlaxoSmithKline and the NIH / NHLBI . S.V. Lynch reports grants from the NIH/National Institute of Allergy and Infectious Diseases (NIAID), NIH / National Institute on Drug Abuse (NIDA), NIH / Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH / Office of the Director , and the Crohn's and Colitis Foundation of America; reports personal fees from Siolta Therapeutics outside the submitted work; has a patent “Reductive prodrug cancer chemotherapy (Stan449-PRV)" issued, a patent “Combination antibiotic and antibody therapy for the treatment of Pseudomonas aeruginosa infection (WO2010091189A1)" with royalties paid by KaloBios, a patent “Therapeutic microbial consortium for induction of immune tolerance” licensed to Siolta Therapeutics, a patent “Systems and methods for detecting antibiotic resistance (WO2012027302A3)" issued, a patent “Nitroreductase enzymes (US7687474B2)" issued, a patent “Sinusitis diagnostics and treatments (WO2013155370A1)" licensed by Reflourish, and a patent “Methods and systems for phylogenetic analysis (US20120264637A1)" issued; and is a cofounder of Siolta Therapeutics, a startup developing a mixed-species microbial oral therapeutic for induction of immune tolerance. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, under contract and grant numbers HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, and UM2AI117870. Additional support was provided by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, under grants NIH/NIAID 5R01AI098077; National Center for Advancing Translational Sciences (NCATS)/NIH UL1TR000150; and National Center for Research Resources (NCRR)/NCATS/NIH UL1TR000077-04, UL1TR000451, UL1TR001105, UL1TR000040, UM1AI109565, UL1TR000075, 1UL1RR025780, UL1TR000154 and UL1TR001082. The following were donated: omalizumab and matching placebo by Novartis and fluticasone and matching placebo by GlaxoSmithKline under a clinical trial agreement with the University of Wisconsin–Madison; EpiPens by Mylan; and Ayr nasal rinse by B.F. Ascher & Company. None of these companies had a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit for publication.Disclosure of potential conflict of interest: All authors, with the exception of A. Togias, report grants from the National Institutes of Health (NIH) during the conduct of study. R. Valladares reports personal fees for employment with Siolta Therapeutics outside the submitted work. H. T. Tran reports personal fees from GlaxoSmithKline outside the submitted work. J. Pongracic reports provision of study drug for other asthma and allergy studies from GlaxoSmithKline, Boehringer Ingelheim, and Genentech/Novartis outside the submitted work. C. M. Kercsmar reports personal fees from GlaxoSmithKline for service on a DSMB and royalties from UpToDate outside the submitted work. M. Gill reports honoraria and support for travel from the American Academy of Allergy, Asthma & Immunology (AAAAI), as well as payment for lectures from the American Academy of Pediatrics outside the submitted work. A. H. Liu reports personal fees from Merck Sharp & Dohme and Phadia Thermo-Fisher and membership on a Data Monitoring Committee for GlaxoSmithKline outside the submitted work. M. Kattan reports personal feed from Novartis Pharma and Regeneron for service on advisory boards outside the submitted work. S. J. Teach reports grants from Patient-Centered Outcomes Research Institute (PCORI), EJF, and the NIH/National Heart, Lung, and Blood Institute (NHLBI) outside the submitted work and personal fees from UpToDate outside the submitted work. H. A. Boushey serves as a compensated member of a Scientific Advisory Committee for Siolta Therapeutics. J. E. Gern reports personal fees from PREP Biopharm, Regeneron, Meissa Vaccines, MedImmune, and Ena Pharmaceuticals, as well as stock options from Meissa Vaccines outside the submitted work and has a patent “Methods of Propagating Rhinovirus C in Previously Unsusceptible Cell Lines” issued and a patent “Adapted Rhinovirus C” pending outside the submitted work. D. J. Jackson reports personal fees from Novartis, Boehringer Ingelheim, Pfizer, Commense, and Sanofi/Genzyme outside the submitted work, as well as grants from GlaxoSmithKline and the NIH/NHLBI. S.V. Lynch reports grants from the NIH/National Institute of Allergy and Infectious Diseases (NIAID), NIH/National Institute on Drug Abuse (NIDA), NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH/Office of the Director, and the Crohn's and Colitis Foundation of America; reports personal fees from Siolta Therapeutics outside the submitted work; has a patent “Reductive prodrug cancer chemotherapy (Stan449-PRV)" issued, a patent “Combination antibiotic and antibody therapy for the treatment of Pseudomonas aeruginosa infection (WO2010091189A1)" with royalties paid by KaloBios, a patent “Therapeutic microbial consortium for induction of immune tolerance” licensed to Siolta Therapeutics, a patent “Systems and methods for detecting antibiotic resistance (WO2012027302A3)" issued, a patent “Nitroreductase enzymes (US7687474B2)" issued, a patent “Sinusitis diagnostics and treatments (WO2013155370A1)" licensed by Reflourish, and a patent “Methods and systems for phylogenetic analysis (US20120264637A1)" issued; and is a cofounder of Siolta Therapeutics, a startup developing a mixed-species microbial oral therapeutic for induction of immune tolerance. The rest of the authors declare that they have no relevant conflicts of interest. We thank the PROSE participants for their contribution to this study. Sequence data are available on the European Nucleotide Archive under accession number PRJEB25616. Funding Information: Supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) , Department of Health and Human Services , under contract and grant numbers HHSN272200900052C , HHSN272201000052I , 1UM1AI114271-01 , and UM2AI117870 . Additional support was provided by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH , under grants NIH/NIAID 5R01AI098077 ; National Center for Advancing Translational Sciences (NCATS)/ NIH UL1TR000150 ; and National Center for Research Resources (NCRR)/NCATS/ NIH UL1TR000077-04, UL1TR000451 , UL1TR001105 , UL1TR000040 , UM1AI109565 , UL1TR000075 , 1UL1RR025780 , UL1TR000154 and UL1TR001082 . The following were donated: omalizumab and matching placebo by Novartis and fluticasone and matching placebo by GlaxoSmithKline under a clinical trial agreement with the University of Wisconsin–Madison; EpiPens by Mylan; and Ayr nasal rinse by B.F. Ascher & Company. None of these companies had a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit for publication. Funding Information: Supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, under contract and grant numbers HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, and UM2AI117870. Additional support was provided by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, under grants NIH/NIAID 5R01AI098077; National Center for Advancing Translational Sciences (NCATS)/NIH UL1TR000150; and National Center for Research Resources (NCRR)/NCATS/NIH UL1TR000077-04, UL1TR000451, UL1TR001105, UL1TR000040, UM1AI109565, UL1TR000075, 1UL1RR025780, UL1TR000154 and UL1TR001082. The following were donated: omalizumab and matching placebo by Novartis and fluticasone and matching placebo by GlaxoSmithKline under a clinical trial agreement with the University of Wisconsin?Madison; EpiPens by Mylan; and Ayr nasal rinse by B.F. Ascher & Company. None of these companies had a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit for publication.Disclosure of potential conflict of interest: All authors, with the exception of A. Togias, report grants from the National Institutes of Health (NIH) during the conduct of study. R. Valladares reports personal fees for employment with Siolta Therapeutics outside the submitted work. H. T. Tran reports personal fees from GlaxoSmithKline outside the submitted work. J. Pongracic reports provision of study drug for other asthma and allergy studies from GlaxoSmithKline, Boehringer Ingelheim, and Genentech/Novartis outside the submitted work. C. M. Kercsmar reports personal fees from GlaxoSmithKline for service on a DSMB and royalties from UpToDate outside the submitted work. M. Gill reports honoraria and support for travel from the American Academy of Allergy, Asthma & Immunology (AAAAI), as well as payment for lectures from the American Academy of Pediatrics outside the submitted work. A. H. Liu reports personal fees from Merck Sharp & Dohme and Phadia Thermo-Fisher and membership on a Data Monitoring Committee for GlaxoSmithKline outside the submitted work. M. Kattan reports personal feed from Novartis Pharma and Regeneron for service on advisory boards outside the submitted work. S. J. Teach reports grants from Patient-Centered Outcomes Research Institute (PCORI), EJF, and the NIH/National Heart, Lung, and Blood Institute (NHLBI) outside the submitted work and personal fees from UpToDate outside the submitted work. H. A. Boushey serves as a compensated member of a Scientific Advisory Committee for Siolta Therapeutics. J. E. Gern reports personal fees from PREP Biopharm, Regeneron, Meissa Vaccines, MedImmune, and Ena Pharmaceuticals, as well as stock options from Meissa Vaccines outside the submitted work and has a patent ?Methods of Propagating Rhinovirus C in Previously Unsusceptible Cell Lines? issued and a patent ?Adapted Rhinovirus C? pending outside the submitted work. D. J. Jackson reports personal fees from Novartis, Boehringer Ingelheim, Pfizer, Commense, and Sanofi/Genzyme outside the submitted work, as well as grants from GlaxoSmithKline and the NIH/NHLBI. S.V. Lynch reports grants from the NIH/National Institute of Allergy and Infectious Diseases (NIAID), NIH/National Institute on Drug Abuse (NIDA), NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH/Office of the Director, and the Crohn's and Colitis Foundation of America; reports personal fees from Siolta Therapeutics outside the submitted work; has a patent ?Reductive prodrug cancer chemotherapy (Stan449-PRV)" issued, a patent ?Combination antibiotic and antibody therapy for the treatment of Pseudomonas aeruginosa infection (WO2010091189A1)" with royalties paid by KaloBios, a patent ?Therapeutic microbial consortium for induction of immune tolerance? licensed to Siolta Therapeutics, a patent ?Systems and methods for detecting antibiotic resistance (WO2012027302A3)" issued, a patent ?Nitroreductase enzymes (US7687474B2)" issued, a patent ?Sinusitis diagnostics and treatments (WO2013155370A1)" licensed by Reflourish, and a patent ?Methods and systems for phylogenetic analysis (US20120264637A1)" issued; and is a cofounder of Siolta Therapeutics, a startup developing a mixed-species microbial oral therapeutic for induction of immune tolerance. The rest of the authors declare that they have no relevant conflicts of interest. Publisher Copyright: © 2019
PY - 2019/11
Y1 - 2019/11
N2 - Background: In infants, distinct nasopharyngeal bacterial microbiotas differentially associate with the incidence and severity of acute respiratory tract infection and childhood asthma development. Objective: We hypothesized that distinct nasal airway microbiota structures also exist in children with asthma and relate to clinical outcomes. Methods: Nasal secretion samples (n = 3122) collected after randomization during the fall season from children with asthma (6-17 years, n = 413) enrolled in a trial of omalizumab (anti-IgE) underwent 16S rRNA profiling. Statistical analyses with exacerbation as the primary outcome and rhinovirus infection and respiratory illnesses as secondary outcomes were performed. Using A549 epithelial cells, we assessed nasal isolates of Moraxella, Staphylococcus, and Corynebacterium species for their capacity to induce epithelial damage and inflammatory responses. Results: Six nasal airway microbiota assemblages, each dominated by Moraxella, Staphylococcus, Corynebacterium, Streptococcus, Alloiococcus, or Haemophilus species, were observed. Moraxella and Staphylococcus species–dominated microbiotas were most frequently detected and exhibited temporal stability. Nasal microbiotas dominated by Moraxella species were associated with increased exacerbation risk and eosinophil activation. Staphylococcus or Corynebacterium species–dominated microbiotas were associated with reduced respiratory illness and exacerbation events, whereas Streptococcus species–dominated assemblages increased the risk of rhinovirus infection. Nasal microbiota composition remained relatively stable despite viral infection or exacerbation; only a few taxa belonging to the dominant genera exhibited relative abundance fluctuations during these events. In vitro, Moraxella catarrhalis induced significantly greater epithelial damage and inflammatory cytokine expression (IL-33 and IL-8) compared with other dominant nasal bacterial isolates tested. Conclusion: Distinct nasal airway microbiotas of children with asthma relate to the likelihood of exacerbation, rhinovirus infection, and respiratory illnesses during the fall season.
AB - Background: In infants, distinct nasopharyngeal bacterial microbiotas differentially associate with the incidence and severity of acute respiratory tract infection and childhood asthma development. Objective: We hypothesized that distinct nasal airway microbiota structures also exist in children with asthma and relate to clinical outcomes. Methods: Nasal secretion samples (n = 3122) collected after randomization during the fall season from children with asthma (6-17 years, n = 413) enrolled in a trial of omalizumab (anti-IgE) underwent 16S rRNA profiling. Statistical analyses with exacerbation as the primary outcome and rhinovirus infection and respiratory illnesses as secondary outcomes were performed. Using A549 epithelial cells, we assessed nasal isolates of Moraxella, Staphylococcus, and Corynebacterium species for their capacity to induce epithelial damage and inflammatory responses. Results: Six nasal airway microbiota assemblages, each dominated by Moraxella, Staphylococcus, Corynebacterium, Streptococcus, Alloiococcus, or Haemophilus species, were observed. Moraxella and Staphylococcus species–dominated microbiotas were most frequently detected and exhibited temporal stability. Nasal microbiotas dominated by Moraxella species were associated with increased exacerbation risk and eosinophil activation. Staphylococcus or Corynebacterium species–dominated microbiotas were associated with reduced respiratory illness and exacerbation events, whereas Streptococcus species–dominated assemblages increased the risk of rhinovirus infection. Nasal microbiota composition remained relatively stable despite viral infection or exacerbation; only a few taxa belonging to the dominant genera exhibited relative abundance fluctuations during these events. In vitro, Moraxella catarrhalis induced significantly greater epithelial damage and inflammatory cytokine expression (IL-33 and IL-8) compared with other dominant nasal bacterial isolates tested. Conclusion: Distinct nasal airway microbiotas of children with asthma relate to the likelihood of exacerbation, rhinovirus infection, and respiratory illnesses during the fall season.
KW - 16S rRNA
KW - Microbiota
KW - Moraxella species
KW - Staphylococcus species
KW - airway
KW - asthma
KW - exacerbation
KW - rhinovirus
UR - http://www.scopus.com/inward/record.url?scp=85069170764&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2019.05.035
DO - 10.1016/j.jaci.2019.05.035
M3 - Article
C2 - 31201890
AN - SCOPUS:85069170764
SN - 0091-6749
VL - 144
SP - 1187
EP - 1197
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 5
ER -